Crispr Therapeutics (NASDAQ:CRSP) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a report released on Thursday.
A number of other research analysts have also weighed in on CRSP. Zacks Investment Research lowered shares of Crispr Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, November 12th. SunTrust Banks reaffirmed a “buy” rating on shares of Crispr Therapeutics in a research note on Monday, December 31st. Needham & Company LLC began coverage on shares of Crispr Therapeutics in a research note on Sunday, December 9th. They issued a “buy” rating and a $38.72 target price on the stock. Wells Fargo & Co began coverage on shares of Crispr Therapeutics in a research note on Wednesday, October 10th. They issued an “outperform” rating and a $65.00 target price on the stock. Finally, Raymond James began coverage on shares of Crispr Therapeutics in a research note on Thursday, September 20th. They issued an “underperform” rating on the stock. One analyst has rated the stock with a sell rating, four have given a hold rating and ten have issued a buy rating to the stock. Crispr Therapeutics has an average rating of “Buy” and a consensus target price of $59.19.
Crispr Therapeutics stock traded up $0.58 during midday trading on Thursday, reaching $35.15. The company had a trading volume of 446,591 shares, compared to its average volume of 1,017,600. The firm has a market capitalization of $1.91 billion, a PE ratio of -20.56 and a beta of 3.48. Crispr Therapeutics has a 12-month low of $22.22 and a 12-month high of $73.90.
In other news, President Rodger Novak sold 17,310 shares of the firm’s stock in a transaction that occurred on Tuesday, January 8th. The shares were sold at an average price of $35.09, for a total transaction of $607,407.90. Following the completion of the sale, the president now owns 1,130,697 shares in the company, valued at approximately $39,676,157.73. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Vertex Pharmaceuticals (Europe purchased 40,198 shares of the business’s stock in a transaction dated Thursday, December 27th. The shares were purchased at an average price of $24.93 per share, with a total value of $1,002,136.14. The disclosure for this purchase can be found here. Insiders acquired a total of 153,682 shares of company stock worth $3,700,718 over the last three months. Corporate insiders own 37.70% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Signaturefd LLC increased its holdings in shares of Crispr Therapeutics by 123.8% during the 2nd quarter. Signaturefd LLC now owns 2,350 shares of the company’s stock worth $138,000 after buying an additional 1,300 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of Crispr Therapeutics by 26.5% during the 2nd quarter. Bank of America Corp DE now owns 9,407 shares of the company’s stock worth $553,000 after buying an additional 1,972 shares during the last quarter. TRUE Private Wealth Advisors acquired a new stake in shares of Crispr Therapeutics during the 3rd quarter worth approximately $122,000. Vanguard Group Inc. increased its holdings in shares of Crispr Therapeutics by 6.6% during the 3rd quarter. Vanguard Group Inc. now owns 52,023 shares of the company’s stock worth $2,307,000 after buying an additional 3,200 shares during the last quarter. Finally, Vanguard Group Inc increased its holdings in shares of Crispr Therapeutics by 6.6% during the 3rd quarter. Vanguard Group Inc now owns 52,023 shares of the company’s stock worth $2,307,000 after buying an additional 3,200 shares during the last quarter. Institutional investors and hedge funds own 43.81% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
Recommended Story: Conference Calls
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.